Search

Your search keyword '"Luo, Tian‐Qi"' showing total 21 results
Start Over Author "Luo, Tian‐Qi"
21 results on '"Luo, Tian‐Qi"'

10. Adjuvant Chemotherapy for Patients with Adenocarcinoma of the Esophagogastric Junction: A Retrospective, Multicenter, Observational Study.

Author

Nie, Run-Cong, Luo, Tian-Qi, Li, Guo-Dong, Zhang, Fei-Yang, Chen, Guo-Ming, Li, Jin-Xing, Chen, Xiao-Jiang, Zhao, Zhou-Kai, Jiang, Kai-Ming, Wei, Yi-Cheng, Huang, Ming-Wei, Chen, Shi, and Chen, Ying-Bo

Abstract

Background: Although the incidence of adenocarcinoma of the esophagogastric junction (AEG) has been increasing since the past decade, the proportion of AEG cases in two previous clinical trials (ACTS-GC and CLASSIC) that investigated the efficacy of adjuvant chemotherapy was relatively small. Therefore, whether AEG patients can benefit from adjuvant chemotherapy remains unclear. Methods: Patients who were diagnosed with pathological stage II/III, Siewert II/III AEG, and underwent curative surgery at three high-volume institutions were assessed. Clinical outcomes were analyzed by using Kaplan-Meier curves, log-rank test, and Cox regression model. Propensity score matching (PSM) was used to reduce the selection bias. Results: A total of 927 patients were included (the chemotherapy group: 696 patients; the surgery-only group: 231 patients). The median follow-up was 39.0 months. The 5-year overall survival was 63.1% (95% confidence interval [CI]: 59.0-67.6%) for the chemotherapy group and 50.2% in the surgery-only group (hazard ratio [HR] = 0.69, 95% CI: 0.54-0.88; p = 0.003). The 5-year, disease-free survival was 35.4% for the chemotherapy group and 16.6% for the surgery-only group (HR = 0.66, 95% CI: 0.53-0.83; p < 0.001). After PSM, the survival benefit of adjuvant chemotherapy for AEG was maintained. Multivariate analysis for overall survival and disease-free survival further demonstrated the survival benefit of adjuvant chemotherapy, with HRs of 0.63 (p < 0.001) and 0.52 (p < 0.001), respectively. Conclusions: Postoperative adjuvant chemotherapy was associated with improved overall survival and disease-free survival in patients with operable stage II or III AEG after D2 gastrectomy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

11. Adjuvant Chemotherapy for Patients with Adenocarcinoma of the Esophagogastric Junction: A Retrospective, Multi-Center Observational

Author

Nie, Runcong, primary, Luo, Tian-qi, additional, Li, Guo-Dong, additional, Zhang, Fei-Yang, additional, Chen, Guo-Ming, additional, Li, Jin-Xing, additional, Chen, Xiao-Jiang, additional, Zhao, Zhou-Kai, additional, Jiang, Kai-Ming, additional, Wei, Yi-Cheng, additional, Chen, Shi, additional, and Chen, Yingbo, additional

Published
2022
Full Text
View/download PDF

15. Supplementary_materials_2 – Supplemental material for Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma

Author

Run-Cong Nie, Yuan, Shu-Qiang, Wang, Yun, Zou, Xue-Bin, Chen, Shi, Li, Shu-Man, Duan, Jin-Ling, Zhou, Jie, Chen, Guo-Ming, Luo, Tian-Qi, Zhou, Zhi-Wei, and Li, Yuan-Fang

Subjects
110203 Respiratory Diseases, viruses, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, Supplementary_materials_2 for Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma by Run-Cong Nie, Shu-Qiang Yuan, Yun Wang, Xue-Bin Zou, Shi Chen, Shu-Man Li, Jin-Ling Duan, Jie Zhou, Guo-Ming Chen, Tian-Qi Luo, Zhi-Wei Zhou and Yuan-Fang Li in Therapeutic Advances in Medical Oncology

Published
2020
Full Text
View/download PDF

16. Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: evidence from 20 randomized controlled trials

Author

Nie, Run-Cong, primary, Zou, Xue-Bin, additional, Yuan, Shu-Qiang, additional, Chen, Ying-Bo, additional, Chen, Shi, additional, Chen, Yong-Ming, additional, Chen, Guo-Ming, additional, Chen, Xiao-Jiang, additional, Luo, Tian-Qi, additional, Li, Shu-Man, additional, Duan, Jin-Ling, additional, Wang, Yun, additional, and Li, Yuan-Fang, additional

Published
2020
Full Text
View/download PDF

19. Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: evidence from 20 randomized controlled trials

Author

Nie, Run-Cong, primary, Zou, Xue-Bin, additional, Yuan, Shu-Qiang, additional, Chen, Ying-Bo, additional, Chen, Shi, additional, Chen, Yong-Ming, additional, Chen, Guo-Ming, additional, Chen, Xiao-Jiang, additional, Luo, Tian-Qi, additional, Li, Shu-Man, additional, Duan, Jin-Ling, additional, Zhou, Zhi-Wei, additional, and Li, Yuan-Fang, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results